loader2
Partner With Us NRI

Innova Captab Ltd share Price Today

Company details

501.00
549.40
421.35
588.00
6M Return -1.23%
1Y Return -4.97%
Mkt Cap.(Cr) 2,944.23
Volume 298,210
Div Yield 0.00%
OI
-
OI Chg %
-
Volume 298,210

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500

Pharmaceuticals company Innova Captab announced Q4FY24 & FY24 results:

Q4FY24 Financial Highlights:

  • Revenue from operation is Rs 262.63 crore in Q4FY24 as against Rs 240.95 crore of previous year registering a growth of 9.0%.
  • The Company’s EBITDA stood at Rs 43.76 crore in Q4FY24 against Rs 29.42 crore of previous year registering a growth of 48.7%.
  • Profit After Tax (PAT) stood at Rs 28.72 crore in Q4FY24 against Rs 17.25 crore of previous year registering a growth of 66.5%.

FY24 Financial Highlights:

  • Total Income for the FY24 stood at Rs 1,093.79 crore against Rs 935.58 crore in FY23 with growth of 16.9% over FY23.
  • Revenue from Operation has increased to Rs 1,081.31 crore in FY24 from Rs 926.38 crore in FY23, registering a growth of 16.7%.
  • The Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) stands at Rs 166.94 crore in FY24, as against Rs 122.85 crore in FY23, with an increase of 35.9%.
  • Profit After Tax (PAT) is Rs 94.35 crore in FY24 as against Rs 67.95 crore in FY23, registering a growth of 38.9%.
  • Earnings per share (EPS) for FY24 is Rs 18.66, against Rs 14.16 in FY23
  • For FY24, net cash generated from operating activities stood at Rs 146 crore, against Rs 67 crore in FY23.

Commenting on the results, Vinay Lohariwala, Managing Director, - Innova Captab Limited said, For FY24, we reported a total income of Rs 1,094 crore with a growth of 16.9% compared to the previous year. Our all business areas are getting good traction and are expected to grow at a healthy rate in the coming years.

Over the last 3-4 years, we have grown at a healthy rate of ~ 20% CAGR. With our upcoming Jammu facility and recent Sharon acquisition, we are positively looking forward to maintaining the same healthy growth rate over the next 3-4 years.

As a company we continue to drive sustainable growth by exploring new opportunities and focusing on value-added products. Indian pharmaceutical companies are set to experience significant growth in the mid to long term, as both domestic and global manufacturers seek reliable and sustainable suppliers like us.

Result PDF

View Other Company Results

Innova Captab Ltd shares SWOT Analysis

Strengths (11)

  • MACD Crossover Above Signal Line
  • Rising Net Cash Flow and Cash from Operating activity
  • Company with high TTM EPS Growth

Weakness (4)

  • MFs decreased their shareholding last quarter
  • Inefficient use of capital to generate profits - RoCE declining in the last 2 years
  • Inefficient use of shareholder funds - ROE declining in the last 2 years

Opportunity (2)

  • RSI indicating price strength
  • High Volume, High Gain

Threats (1)

  • Increasing Trend in Non-Core Income

Resistance and support

R1 542.3
R2 570.0
R3 590.7
Pivot

521.63

S1 493.9
S2 473.2
S3 445.5
EMA SMA
504.6
497.0
500.7
-
505.7
492.5
490.8
-
Delivery and volume
CLIENT NAME DEAL TYPE ACTION DATE AVG. PRICE QUANTITY EXCHANGE
GRAVITON RESEARCH CAPITAL LLP Bulk Purchase 2024-01-02 566 345941 NSE
GRAVITON RESEARCH CAPITAL LLP Bulk Sell 2024-01-02 565.55 345941 NSE
GRAVITON RESEARCH CAPITAL LLP Bulk Purchase 2024-01-01 525.68 477528 NSE
Name Category Shares
MANOJ LOHARIWALA PROMOTER 29.07%
VINAY KUMAR LOHARIWALA PROMOTER 21.81%

FINANCIALS

Sales
Operating Profit
Profit after Tax
Equity
Reserves and Surplus
Debt
Sales
Operating Profit
Profit after Tax
PE
Debt/Equity
P BV

Innova Captab Ltd Stocks COMPARISON

Financials( in Cr) Innova Captab Ltd Sun Pharmaceuticals Industries Ltd Cipla Ltd Divis Laboratories Ltd Zydus Lifesciences Ltd
Price 514.50 1,579.30 1,510.40 4,570.80 1,184.80
% Change 2.07 -1.20 -0.19 -1.43 0.39
Mcap Cr 2,944.23 378,926.98 121,944.71 121,340.57 119,218.60
Revenue TTM Cr 926.38 48,496.85 15,790.60 7,845.00 19,547.40
Net Profit TTM Cr 67.95 9,648.44 2,513.47 1,600.00 3,854.40
PE TTM 31.23 37.93 28.66 75.74 30.89
1 Year Return -4.97 51.13 48.56 25.57 103.71
ROCE 23.92 17.20 14.76 16.41 23.94
ROE 28.01 16.13 10.66 12.15 20.64
INSIDER & INSTITUTIONAL ACTIVITY

Equity Capital: 323.36 Cr FV: 10.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 21,424.68 50,451.86
LAST 3M 100,072.29 51,097.20
LAST 6M 183,053.48 43,859.44
LAST 12M 309,832.68 84,987.81

Innova Captab Ltd Information

Stock PE (TTM)
31.23
Promoter Holding
50.9%
Book Value
145.1981
ROCE
23.92%
ROE
28.01%
Description
  • Innova Captab Ltd was incorporated as `Harun Health Care Private Limited`, dated January 3, 2005 at Mumbai. Thereafter, name of the Company changed from `Harun Health Care Private Limited` to `Innova Captab Private Limited`, and consequently, a fresh Certificate of Incorporation dated February 2, 2010, was issued by RoC to the Company. Subsequently, Company converted to a Public Company on July 12, 2018, and consequently, its name was changed to `Innova Captab Limited`, dated July 26, 2018. The Company is an integrated pharmaceutical company in India with a presence across the pharmaceuticals value chain including research and development, manufacturing, drug distribution and marketing and exports. Their business includes contract development and manufacturing organization (CDMO) business providing manufacturing services to Indian pharmaceutical companies, domestic branded generics business and an international branded generics business. Their CDMO product portfolio spans across both acute and chronic therapeutic areas. These CDMO services and products include commercial large-scale manufacturing of generic products, which allow customers in offering multiple dosage forms, including oral solids, oral liquids, dry syrups and injectables, modified and release forms of tablets in capsules. It has 2 manufacturing facilities in Baddi, Himachal Pradesh. Their facilities further produce tablets, capsules, dry syrups, dry powder injections, ointments and liquid orals. In 2006, the first manufacturing plant got established in Baddi, at Himachal Pradesh. In 2010, it commenced operations at the cephalosporin block of their plant in Baddi. In 2021, the Company acquired business of Innova Captab, a Partnership Firm effective as of March 31, 2021 and acquired Univentis Medicare Limited (UML) 100% equity shares effective on December 31, 2021 and consequently, The Univentis Foundation became a Subsidiary of Company on June 14, 2021. The Company is planning to raise capital from Public by raising 400 crore Equity Shares through Fresh Issue and 9,600,000 Equity Shares through Offer for Sale.

No Data Found

AGM Date (Month) :
Face Value Equity Shares : 10
Market Lot Equity Shares : 1
BSE Code : 544067
NSE Code : INNOVACAP
Book Closure Date (Month) :
BSE Group : B
ISIN : INE0DUT01020

FAQ’s on Innova Captab Ltd Shares

You can buy Innova Captab Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Innova Captab Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Jul 16, 2024 03:55 PM the closing price of Innova Captab Ltd was Rs.514.50.

The latest PE ratio of Innova Captab Ltd as of Jul 16, 2024 03:55 PM is 31.23

The latest PB ratio of Innova Captab Ltd as of Jul 16, 2024 03:55 PM is 0.28

The 52-week high of Innova Captab Ltd share price is Rs. 588.00 while the 52-week low is Rs. 421.35

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of Jul 16, 2024 03:55 PM, the market cap of Innova Captab Ltd stood at Rs. 2,944.23 Cr.

Download App

Download Our App

Play Store App Store
market app